

527 Industrial Way West
Eatontown, NJ 07724
732.389.4500 | fax 732.389.4998

NEWS RELEASE

www.lanmarkgroup.com



Client/Product:
For Release: *LED Medical Diagnostics Inc./Semmelmayer*
Contact: **Draft**
Michael Ventriello
mventriello@lanmarkgroup.com

**STEVEN J. SEMMELMAYER NAMED PRESIDENT AND CEO OF
LED MEDICAL DIAGNOSTICS INC. AND ITS SUBSIDIARY, LED DENTAL INC.**

***FORMER PRESIDENT OF SYBRON DENTAL SPECIALTIES PROFESSIONAL DENTAL GROUP,
TAKING THE HELM OF CANADIAN MEDICAL DEVICE COMPANY***

British Columbia, Canada – January 26, 2007 – LED Medical Diagnostics Inc., a Vancouver-based company that commercializes medical screening devices utilizing its proprietary fluorescence imaging platform to aid in the early detection of cancerous and precancerous lesions, recently appointed Steven J. Semmelmayer as its president and CEO. Semmelmayer was also named president and CEO of LED Dental Inc., a wholly-owned subsidiary that manufactures the VELscope[®] oral mucosal examination device.

Semmelmayer most recently served as president of Sybron Dental Specialties Professional Dental Group, a market-leading global manufacturer of professional medical and dental products. He started his career with Ormco Orthodontics when it had sales of \$40 million, and through acquisition and internal growth it became a \$780 million public company that was recently sold to Danaher Corporation for \$2.2 billion. During his career, Semmelmayer led 19 acquisitions of dental, medical infection control and magnification companies.

According to Peter Whitehead, founder of LED Medical Diagnostics and LED Dental Inc. and the co-developer of Direct Optical Fluorescence Visualization Technology with the British Columbia Cancer Agency, "Steven is known to be a business builder. This is the type of leadership LED Medical Diagnostics needs to grow as a company and to apply our proprietary technology to the development of a variety of medical screening devices."

For example, in 2006, LED Medical Diagnostics subsidiary LED Dental Inc. successfully

-more-

(2)

introduced its Visually Enhanced Lesion Scope – or VELscope® – oral mucosal examination device to dental clinicians. The company expects that its Direct Tissue Fluorescence Visualization Technology will have great potential beyond the VELscope application and can be potentially incorporated in screening devices used by gynecologists, gastroenterologists, ENT specialists, dermatologists, and family practitioners.

In his new role at LED Medical Diagnostics Inc. and LED Dental Inc., Semmelmayr will assume overall responsibility for developing the strategies and tactics needed for growing both divisions, including developing products that meet clinical needs.

“LED Medical is an exciting young company with breakthrough technology that can have a positive impact on countless lives,” said Semmelmayr. “I believe my experience and leadership philosophy are a good cultural fit that will help develop LED Medical’s business and people to create the most value for all of our stakeholders”

About LED Medical Diagnostics

LED Medical Diagnostics (founded in 2003) is headquartered in Vancouver, British Columbia, Canada. The company develops and markets medical screening devices based on its proprietary Direct Tissue Fluorescence Visualization Technology platform to aid in the early detection of mucosal tissue abnormalities, including malignant and pre-malignant lesions, to facilitate timely diagnosis and treatment. The company’s wholly-owned subsidiary, LED Dental Inc., manufactures the VELscope® oral mucosal examination device. For more information call 1-888-541-4614 or visit

www.VELscope.com

LED Medical Diagnostics Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well

-more-

(3)

as information included in oral statements or other written statements made or to be made by the company) contains statements that are forward-looking, such as statements relating to anticipated future revenues of the company and success of current product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of the company. For a description of additional risks and uncertainties, please refer to the company's filings with the Securities and Exchange Commission.

###